SCHEMBL30375696

SCHEMBL30375696

O=c1[nH]ncc2cc(S)ccc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
HSD17B10 Q99714 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
PARP1 P09874 1/20 0.56
PRKCI P41743 1/20 0.56
PDE4B Q07343 1/20 0.56
MAPK1 P28482 3/20 0.35
KDM4E B2RXH2 3/20 0.35
HPGD P15428 2/20 0.35
MKNK1 Q9BUB5 1/20 0.35
XDH P47989 2/20 0.34
RAB9A P51151 2/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
ADORA2A P29274 1/20 0.34
SLC6A4 P31645 1/20 0.34
ADRA1A P35348 1/20 0.34
BLM P54132 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
SLC2A1 P11166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25184048 1.00 ALDH1A1 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL29655244 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL29735151 0.78 METAP2 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL601322 0.78 NOS1 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL31331121 0.78 PARP1 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL396016 0.78 METAP2 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL4060395 0.78 PARP1 (0.61) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL15577321 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL1008698 0.78 ALDH1A1 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI
SCHEMBL27460088 0.78 PARP1 (0.56) ALDH1A1HSD17B10TDP1PARP1PRKCI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4426681-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2024-09-11 EP claimed
CN-118317951-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2024-07-09 CN claimed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 WO claimed
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2026-03-26 US disclosed
US-12448367-B2 Phthalazine derivatives as pyruvate kinase modulators SITRYX THERAPEUTICS LIMITED (GB) 2025-10-21 US disclosed
US-20250230143-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2025-07-17 US disclosed
CN-120166987-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2025-06-17 CN disclosed
EP-4426681-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS Sitryx Therapeutics Limited (GB) 2024-09-11 EP disclosed
CN-118317951-A Phthalazine derivatives as pyruvate kinase modulators 西特瑞治疗有限公司 2024-07-09 CN disclosed
WO-2023079294-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS SITRYX THERAPEUTICS LIMITED (GB) 2023-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085061-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS PDK1, PDK2, PDK4 ALDH1A1 629/4885HSD17B10 1004/4885TDP1 2114/4885
US-20250230143-A1 PHTHALAZINE DERIVATIVES AS PYRUVATE KINASE MODULATORS PDK1, PDK2, PDK3 ALDH1A1 1062/4885HSD17B10 453/4885TDP1 2336/4885
US-12448367-B2 Phthalazine derivatives as pyruvate kinase modulators PDK1, PDK2, PDK3 ALDH1A1 1062/4885HSD17B10 453/4885TDP1 2336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.